ClinicalTrials.gg
CompletedNCT03774875EMBRACEUpdated Jul 10, 2025Results posted

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life

A Phase 4 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 72 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.

Enrollment
10th of 44
277 · median 103
Started
2019
with 5 others
Phase 4
14 of 44
3 open now
Registered
27th of 44
by date
Lead sponsor
25 of 44
Amgen

Among the 44 studies testing apremilast in Psoriasis, this one is the 10th largest by enrollment, is one of 6 that started in 2019, is one of 14 in phase 4, and was the 27th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing apremilast in Psoriasis, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the impact of treatment with apremilast 30 mg twice daily for 16 weeks, compared to placebo, on health-related quality of life (QOL) in adults with manifestations of plaque psoriasis and impaired quality of life.

Read the detailed description

Participants will be randomized 2 (apremilast):1 (placebo) in approximately 10 countries in Western Europe. Participants will be block-randomized to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). Participants presenting with multiple manifestations will be allocated to the manifestation which is most severe, as determined by the participant. All manifestations will be assessed for efficacy at each study visit.

The study will consist of 4 phases:

  • Screening Phase - up to 5 weeks (35 days)
  • Double-blind Placebo-controlled Phase - Weeks 0 to 16 Participants will receive treatment with either apremilast or matched placebo.
  • Apremilast Extension Phase - Weeks 16 through 52 All participants will be switched to (or continue with) apremilast at week 16 and will maintain this dosing through week 52.
  • Post-treatment Observational Follow-up Phase 4-week post-treatment observational follow-up phase for all participants who complete the study on treatment or discontinue from the study treatment early.
03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Apremilast
  • CC-10004
  • Quality of life
  • Safety
  • Efficacy
  • Psoriasis manifestations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 18 years of age at the time of signing the form (ICF).
  2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  4. Subject has diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline, that cannot be controlled by topical therapy.
  5. Subject has a PASI score ranging from ≥ 3 to ≤ 10 at baseline.
  6. Subject has a DLQI score > 10 at baseline.
  7. Subject has presence of ≥ 1 clinical manifestations of plaque psoriasis, defined as at least one of the following:

    1. Moderate to severe scalp psoriasis, defined as Scalp Physician Global Assessment (ScPGA) ≥ 3
    2. Nail psoriasis, defined as onycholysis and onychodystrophy in at least 2 fingernails
    3. Moderate to severe genital plaque psoriasis, defined as modified static Physicians Global Assessment of Genitalia (sPGA-G) ≥ 3
    4. Moderate to severe palmoplantar psoriasis, defined as Palmoplantar Psoriasis Physicians Global Assessment (PPPGA) ≥ 3
    5. Moderate to severe plaque psoriasis in visible locations (dorsal hand, face, neck, and hairline) with static Physicians Global Assessment (sPGA) ≥ 3
  8. Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories.

    (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions.)

  9. Subject must have failed to respond to, or be to, or intolerant to other systemic therapy, including, but not limited to, cyclosporine, methotrexate, acitretin, psoralen and ultraviolet-A-light (PUVA) fumaric acid esters or biologic therapies.
  10. Subjects (in Italy only) must be non-responder to, contraindicated to, or intolerant to other systemic therapy (including cyclosporine, methotrexate, or PUVA) AND also be contraindicated to, or intolerant to biologics.
  11. Females of (FCBP) must have a negative pregnancy test at Screening and Baseline. While on product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved options described below:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

NOTE: Option 2 may not be acceptable as a highly effective contraception option in all countries per local guidelines/regulations.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any condition, including other inflammatory diseases or dermatologic conditions, which confounds the ability to interpret data from the study, including other types of psoriasis (ie, erythrodermic, or guttate), other than plaque psoriasis or inverse psoriasis.
  2. Subject has history of drug-induced psoriasis.
  3. Subject has arthritis that requires systemic treatment.
  4. Subject unable to avoid use of tanning booths for at least 4 weeks prior to baseline and during study.
  5. Subject is currently enrolled in any other clinical trial involving an product.
  6. Other than psoriasis, subject has history of or uncontrolled disease (as determined by the Investigator), including the presence of laboratory abnormalities, cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease, which places the subject at unacceptable risk if he/she were to participate in the study
  7. Prior history of suicide attempt at any time in the subject's lifetime prior to signing the , or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
  8. Subjects with severe renal impairment, defined by estimated (eGFR) or (CLcr) less than 30 mL/min, are also categorized as having Stage 4 chronic kidney disease (CKD), and are excluded from the study.
  9. or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell in situ skin carcinomas.
  10. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening and no new or recurrent infections prior to the Baseline Visit.
  11. Subject has received a within 3 months of baseline or plans to do so during study.
  12. Subject is a pregnant or breastfeeding (lactating) woman.
  13. Subject has used topical therapy within 2 weeks of randomization (including, but not limited to, topical , retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, anthralin/dithranol, or moisturizers which contain urea or salicylic acid). Use of phototherapy within 4 weeks prior to randomization. Use of conventional systemic therapy or systemic corticosteroids within 4 weeks prior to randomization, except for conditions other than psoriasis or psoriatic arthritis. Use of biologic therapy within 5 pharmacokinetic half-lives.
  14. Prior treatment with apremilast, or participation in a clinical study, involving apremilast.
  15. Subject has any condition that confounds the ability to interpret data from the study.
  16. Subject has history of allergy or to any components of the IP (including placebo).
  17. Subject has rare hereditary problem of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.
  18. Subject's most severe manifestation corresponds to a manifestation whose randomization block has already been fully enrolled.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg

    Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.

    Drug: Apremilast

  • Placebo comparator
    Placebo / Apremilast 30 mg

    Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.

    Drug: Apremilast · Drug: Placebo

Interventions

  • Apremilast 30 mg tablets taken orally twice a day.

    Also known as: Otezla, CC-10004

  • DrugPlacebo

    Placebo tablets taken orally twice a day

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.

    Time frame: Baseline and week 16

Secondary outcomes

  1. Change From Baseline in DLQI at Week 16

    The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.

    Time frame: Baseline and week 16

  2. Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16

    Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Baseline and week 16

  3. Change From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16

    The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.

    Time frame: Baseline and week 16

  4. Change From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16

    Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.

    Time frame: Baseline and week 16

  5. Percentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 16

    The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Week 16

  6. Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 16

    The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (16 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).

    Time frame: Week 16

  7. Percent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 16

    EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.

    Time frame: Baseline and week 16

  8. Percent Change From Baseline in EQ-5D Index Score at Week 16

    EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.

    Time frame: Baseline and week 16

  9. Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 16

  10. Change From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 16

  11. Change From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 16

  12. Change From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 16

  13. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Placebo-controlled Period

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.

    Time frame: From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period.

  14. Number of Participants With Marked Laboratory Abnormalities During the Placebo-controlled Period

    Marked laboratory abnormalities are defined for each parameter below. ULN = upper limit of normal

    Time frame: 16 weeks

  15. Change From Baseline in Blood Pressure During the Placebo-controlled Period

    Time frame: Baseline, week 2, week 4, and week 16

  16. Change From Baseline in Pulse Rate During the Placebo-controlled Period

    Time frame: Baseline and week 2, week 4, and week 16

  17. Change From Baseline in Body Weight During the Placebo-controlled Period

    Time frame: Baseline and week 2, week 4, and week 16

  18. Change From Baseline in Waist Circumference During the Placebo-controlled Period

    Time frame: Baseline and week 2, week 4, and week 16

  19. Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in DLQI at Weeks 32 and 52

    The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.

    Time frame: Baseline, week 32 and week 52

  20. Change From Baseline in DLQI at Weeks 32 and 52

    The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.

    Time frame: Baseline, week 32 and week 52

  21. Change From Baseline in Itch NRS Score at Weeks 32 and 52

    The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.

    Time frame: Baseline, week 32 and week 52

  22. Change From Baseline in Skin Discomfort/Pain VAS at Weeks 32 and 52

    Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.

    Time frame: Baseline, week 32 and week 52

  23. Percent Change From Baseline in BSA Affected by Psoriasis at Weeks 32 and 52

    Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

    Time frame: Baseline, week 32 and week 52

  24. Percentage of Participants Who Achieved a PBI Score of ≥ 1 at Weeks 32 and 52

    The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (32 weeks and 52 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).

    Time frame: Week 32 and week 52

  25. Percentage of Participants Who Achieved a PASI Score < 3 at Weeks 32 and 52

    The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

    Time frame: Week 32 and week 52

  26. Percent Change From Baseline in EQ-5D VAS Score at Week 52

    EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.

    Time frame: Baseline and week 52

  27. Percent Change From Baseline in EQ-5D Index Score at Week 52

    EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.

    Time frame: Baseline and week 52

  28. Change From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 52

  29. Change From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 52

  30. Change From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 52

  31. Change From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment

    The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and week 52

  32. Number of Participants With TEAEs During Apremilast Treatment

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.

    Time frame: From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.

  33. Number of Participants With Marked Laboratory Abnormalities During Apremilast Treatment

    Time frame: From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.

  34. Change From Baseline in Blood Pressure at End of Apremilast Extension Period

    Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52

  35. Change From Baseline in Pulse Rate at End of Apremilast Extension Period

    Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52

  36. Change From Baseline in Body Weight at End of Apremilast Extension Period

    Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52

  37. Change From Baseline in Waist Circumference at End of Apremilast Extension Period

    Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52

07

Results

Posted Jan 13, 2022

Participant flow

Eligible participants were enrolled at 55 centers in France, Germany, Italy, Spain, Switzerland, and the United Kingdom. The study consisted of a 16-week placebo-controlled period and a 36-week apremilast extension period.

Placebo-controlled Period (Week 1-16)
Participant flow — Placebo-controlled Period (Week 1-16)
MilestonePlacebo / Apremilast 30 mgApremilast 30 mg
Started92185
Received study drug91185
Completed69152
Not completed2333
Withdrew: Adverse event816
Withdrew: Lack of efficacy24
Withdrew: Withdrawal by subject1210
Withdrew: Lost to follow-up02
Withdrew: Protocol deviation01
Withdrew: Reason unknown10
Apremilast Extension Period (Week 16-52)
Participant flow — Apremilast Extension Period (Week 16-52)
MilestonePlacebo / Apremilast 30 mgApremilast 30 mg
Started69152
Completed53105
Not completed1647
Withdrew: Adverse event69
Withdrew: Lack of efficacy211
Withdrew: Withdrawal by subject720
Withdrew: Non-compliance with study drug02
Withdrew: Other11
Withdrew: Protocol deviation01
Withdrew: Lost to follow-up03

Outcome measures

PrimaryPercentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.

Time frame:
Baseline and week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
percentage of participantsPlaceboApremilast 30 mg
Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 1641.3 (30.0 to 52.6)73.3 (66.7 to 79.9)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference in response rates: 31.9 · 95% CI 18.6 to 45.2Adjusted difference (apremilast - placebo) in response rates calculated using the weighted average of the treatment differences across the strata with the CMH weights.
SecondaryChange From Baseline in DLQI at Week 16

The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in DLQI at Week 16
score on a scalePlaceboApremilast 30 mg
Change From Baseline in DLQI at Week 16-3.4 ± 0.80-8.7 ± 0.54
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = <0.0001 · Least squares (ls) mean difference: -5.3 · 95% CI -7.15 to -3.43Difference in LS Means = Apremilast - Placebo
SecondaryPercent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16

Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16
percent changePlaceboApremilast 30 mg
Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 1618.5 ± 12.95-19.8 ± 6.58
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0085 · Ls mean difference: -38.4 · 95% CI -66.58 to -10.14LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16

The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16
score on a scalePlaceboApremilast 30 mg
Change From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16-0.9 ± 0.32-2.5 ± 0.21
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = <0.0001 · Ls mean difference: -1.6 · 95% CI -2.34 to -0.86LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16

Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16
score on a scalePlaceboApremilast 30 mg
Change From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16-5.4 ± 3.61-21.5 ± 2.36
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0003 · Ls mean difference: -16.1 · 95% CI -24.63 to -7.60LS Mean Difference = Apremilast - Placebo
SecondaryPercentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 16

The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 16
percentage of participantsPlaceboApremilast 30 mg
Percentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 1626.3 (16.6 to 36.0)39.7 (32.3 to 47.1)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = 0.0328 · Adjusted difference in response rates: 13.5 · 95% CI 1.1 to 25.8The adjusted difference in response rates (Apremilast - Placebo) using the weighted average of the treatment differences across the strata with the CMH weights.
SecondaryPercentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 16

The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (16 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 16
percentage of participantsPlaceboApremilast 30 mg
Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 1639.9 (28.8 to 51.0)76.6 (70.2 to 83.1)
Statistical analysis
  • Placebo vs Apremilast 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference in response rates: 37.0 · 95% CI 24.1 to 49.9Adjusted difference (Apremilast - Placebo) in response rates using the weighted average of the treatment differences across the strata with the CMH weights.
SecondaryPercent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 16

EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 16
percent changePlaceboApremilast 30 mg
Percent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 1618.9 ± 15.9633.8 ± 10.67
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.4216 · Ls mean difference: 14.9 · 95% CI -21.62 to 51.48LS Mean Difference = Apremilast - Placebo
SecondaryPercent Change From Baseline in EQ-5D Index Score at Week 16

EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in EQ-5D Index Score at Week 16
percent changePlaceboApremilast 30 mg
Percent Change From Baseline in EQ-5D Index Score at Week 16165.9 ± 89.8017.8 ± 59.59
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.1559 · Ls mean difference: -148.024 · 95% CI -352.8793 to 56.8304LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent impairment
Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed
percent impairmentPlaceboApremilast 30 mg
Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed-4.1 ± 2.56-0.9 ± 1.54
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.2667 · Ls mean difference: 3.1 · 95% CI -2.43 to 8.73LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent impairment
Change From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment
percent impairmentPlaceboApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment-11.5 ± 3.82-13.9 ± 2.32
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.5620 · Ls mean difference: -2.5 · 95% CI -10.83 to 5.91LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent impairment
Change From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment
percent impairmentPlaceboApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment-13.2 ± 4.35-13.8 ± 2.63
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.8927 · Ls mean difference: -0.6 · 95% CI -10.16 to 8.86LS Mean Difference = Apremilast - Placebo
SecondaryChange From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 16
Reported as:
Least squares mean · percent impairment
Change From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment
percent impairmentPlaceboApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment-13.4 ± 3.66-21.2 ± 2.24
Statistical analysis
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0572 · Ls mean difference: -7.8 · 95% CI -15.90 to 0.24LS Mean Difference = Apremilast - Placebo
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Placebo-controlled Period

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.

Time frame:
From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Placebo-controlled Period
ParticipantsPlaceboApremilast 30 mg
Any TEAE54152
Drug-related TEAE26113
Severe TEAEs110
Serious TEAEs08
Serious drug-related TEAE01
TEAE leading to drug interruption09
TEAE leading to drug withdrawal818
TEAE leading to death00
SecondaryNumber of Participants With Marked Laboratory Abnormalities During the Placebo-controlled Period

Marked laboratory abnormalities are defined for each parameter below. ULN = upper limit of normal

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Marked Laboratory Abnormalities During the Placebo-controlled Period
ParticipantsPlaceboApremilast 30 mg
Alanine Aminotransferase > 3 × ULN02
Albumin < 25 g/L00
Alkaline Phosphatase > 400 U/L00
Aspartate Aminotransferase > 3 × ULN01
Bilirubin (umol/L) > 1.8 × ULN00
Blood Urea Nitrogen > 15 mmol/L02
Calcium < 1.8 mmol/L00
Calcium > 3.0 mmol/L00
Cholesterol > 7.8 mmol/L01
Creatinine > 1.7 × ULN01
Glucose < 2.8 mmol/L00
Glucose > 13.9 mmol/L03
Hemoglobin A1C (Fasting) > 9%03
Lactate Dehydrogenase > 3 × ULN00
Potassium < 3.0 mmol/L00
Potassium > 5.5 mmol/L01
Sodium < 130 mmol/L00
Sodium > 150 mmol/L00
Triglycerides > 3.4 mmol/L66
Hemoglobin: Female < 85 g/L, Male < 105 g/L00
Hemoglobin: Female > 170 g/L, Male > 185 g/L00
Leukocytes < 1.5 × 10^9/L00
Lymphocytes < 0.8 × 10^9/L12
Neutrophils, Segmented < 1.0 × 10^9/L00
Platelets < 75 × 10^9/L01
Platelets > 600 × 10^9/L00
SecondaryChange From Baseline in Blood Pressure During the Placebo-controlled Period
Time frame:
Baseline, week 2, week 4, and week 16
Reported as:
Mean · mmHg
Change From Baseline in Blood Pressure During the Placebo-controlled Period
mmHgPlaceboApremilast 30 mg
Systolic: week 2-0.5 ± 11.170.1 ± 12.44
Systolic: week 41.9 ± 12.290.4 ± 11.88
Systolic: week 162.2 ± 13.771.0 ± 12.66
Diastolic: week 2-0.1 ± 7.89-0.6 ± 8.27
Diastolic: week 41.3 ± 7.62-1.0 ± 9.51
Diastolic: week 160.8 ± 8.290.6 ± 9.12
SecondaryChange From Baseline in Pulse Rate During the Placebo-controlled Period
Time frame:
Baseline and week 2, week 4, and week 16
Reported as:
Mean · beats/minute
Change From Baseline in Pulse Rate During the Placebo-controlled Period
beats/minutePlaceboApremilast 30 mg
Week 20.3 ± 10.823.4 ± 9.75
Week 4-0.4 ± 10.173.5 ± 10.43
Week 161.0 ± 9.972.0 ± 10.99
SecondaryChange From Baseline in Body Weight During the Placebo-controlled Period
Time frame:
Baseline and week 2, week 4, and week 16
Reported as:
Mean · kg
Change From Baseline in Body Weight During the Placebo-controlled Period
kgPlaceboApremilast 30 mg
Week 2-0.02 ± 1.161-0.31 ± 1.188
Week 40.04 ± 1.285-0.57 ± 2.060
Week 160.08 ± 2.337-0.98 ± 2.722
SecondaryChange From Baseline in Waist Circumference During the Placebo-controlled Period
Time frame:
Baseline and week 2, week 4, and week 16
Reported as:
Mean · cm
Change From Baseline in Waist Circumference During the Placebo-controlled Period
cmPlaceboApremilast 30 mg
Week 2-0.2 ± 3.930.2 ± 3.49
Week 4-0.1 ± 4.89-0.3 ± 3.63
Week 160.1 ± 6.16-0.9 ± 5.06
SecondaryPercentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in DLQI at Weeks 32 and 52

The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.

Time frame:
Baseline, week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in DLQI at Weeks 32 and 52
percentage of participantsPlacebo / Apremilast 30 mgApremilast 30 mg
Week 3268.1 (55.8 to 78.8)68.4 (60.4 to 75.7)
Week 5276.8 (65.1 to 86.1)79.6 (72.3 to 85.7)
SecondaryChange From Baseline in DLQI at Weeks 32 and 52

The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.

Time frame:
Baseline, week 32 and week 52
Reported as:
Mean · score on a scale
Change From Baseline in DLQI at Weeks 32 and 52
score on a scalePlacebo / Apremilast 30 mgApremilast 30 mg
Week 32-9.8 ± 8.19-9.9 ± 7.28
Week 52-11.3 ± 7.84-11.2 ± 7.08
SecondaryChange From Baseline in Itch NRS Score at Weeks 32 and 52

The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.

Time frame:
Baseline, week 32 and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Itch NRS Score at Weeks 32 and 52
score on a scalePlacebo / Apremilast 30 mgApremilast 30 mg
Week 32-3.2 ± 3.50-2.8 ± 3.22
Week 52-3.9 ± 3.61-3.3 ± 3.19
SecondaryChange From Baseline in Skin Discomfort/Pain VAS at Weeks 32 and 52

Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.

Time frame:
Baseline, week 32 and week 52
Reported as:
Mean · score on a scale
Change From Baseline in Skin Discomfort/Pain VAS at Weeks 32 and 52
score on a scalePlacebo / Apremilast 30 mgApremilast 30 mg
Week 32-28.4 ± 38.40-22.6 ± 33.71
Week 52-35.0 ± 36.76-31.0 ± 34.77
SecondaryPercent Change From Baseline in BSA Affected by Psoriasis at Weeks 32 and 52

Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.

Time frame:
Baseline, week 32 and week 52
Reported as:
Mean · percent change
Percent Change From Baseline in BSA Affected by Psoriasis at Weeks 32 and 52
percent changePlacebo / Apremilast 30 mgApremilast 30 mg
Week 32-49.5 ± 47.35-40.2 ± 51.79
Week 52-49.9 ± 53.25-32.0 ± 93.09
SecondaryPercentage of Participants Who Achieved a PBI Score of ≥ 1 at Weeks 32 and 52

The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (32 weeks and 52 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PBI Score of ≥ 1 at Weeks 32 and 52
percentage of participantsPlacebo / Apremilast 30 mgApremilast 30 mg
Week 3266.7 (54.3 to 77.6)67.8 (59.7 to 75.1)
Week 5265.2 (52.8 to 76.3)63.8 (55.6 to 71.4)
SecondaryPercentage of Participants Who Achieved a PASI Score < 3 at Weeks 32 and 52

The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.

Time frame:
Week 32 and week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI Score < 3 at Weeks 32 and 52
percentage of participantsPlacebo / Apremilast 30 mgApremilast 30 mg
Week 3258.0 (45.5 to 69.8)40.1 (32.3 to 48.4)
Week 5250.7 (38.4 to 63.0)37.5 (29.8 to 45.7)
SecondaryPercent Change From Baseline in EQ-5D VAS Score at Week 52

EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent change
Percent Change From Baseline in EQ-5D VAS Score at Week 52
percent changePlacebo / Apremilast 30 mgApremilast 30 mg
Percent Change From Baseline in EQ-5D VAS Score at Week 5251.4 ± 132.1333.6 ± 78.53
SecondaryPercent Change From Baseline in EQ-5D Index Score at Week 52

EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent change
Percent Change From Baseline in EQ-5D Index Score at Week 52
percent changePlacebo / Apremilast 30 mgApremilast 30 mg
Percent Change From Baseline in EQ-5D Index Score at Week 52214.103 ± 1799.632811.039 ± 224.3001
SecondaryChange From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent impairment
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed
percent impairmentPlacebo / Apremilast 30 mgApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed-4.6 ± 17.43-3.2 ± 17.11
SecondaryChange From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent impairment
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment
percent impairmentPlacebo / Apremilast 30 mgApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment-21.0 ± 29.82-24.4 ± 26.78
SecondaryChange From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent impairment
Change From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment
percent impairmentPlacebo / Apremilast 30 mgApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment-21.7 ± 30.12-25.3 ± 29.91
SecondaryChange From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment

The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and week 52
Reported as:
Mean · percent impairment
Change From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment
percent impairmentPlacebo / Apremilast 30 mgApremilast 30 mg
Change From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment-32.7 ± 33.94-30.5 ± 27.01
SecondaryNumber of Participants With TEAEs During Apremilast Treatment

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.

Time frame:
From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.
Reported as:
Count of participants · Participants
Number of Participants With TEAEs During Apremilast Treatment
ParticipantsApremilast 30 mg
Any TEAE217
Drug-related TEAE152
Severe TEAEs14
Serious TEAEs18
Serious drug-related TEAE2
TEAE leading to drug interruption19
TEAE leading to drug withdrawal31
TEAE leading to death0
SecondaryNumber of Participants With Marked Laboratory Abnormalities During Apremilast Treatment
Time frame:
From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.
Reported as:
Count of participants · Participants
Number of Participants With Marked Laboratory Abnormalities During Apremilast Treatment
ParticipantsApremilast 30 mg
Alanine Aminotransferase > 3 × ULN2
Albumin < 25 g/L0
Alkaline Phosphatase > 400 U/L0
Aspartate Aminotransferase > 3 × ULN1
Bilirubin > 1.8 × ULN1
Blood Urea Nitrogen > 15 mmol/L2
Calcium < 1.8 mmol/L1
Calcium > 3.0 mmol/L0
Cholesterol > 7.8 mmol/L3
Creatinine > 1.7 × ULN1
Glucose < 2.8 mmol/L0
Glucose > 13.9 mmol/L7
Hemoglobin A1C (Fasting) > 9%3
Lactate Dehydrogenase > 3 × ULN0
Potassium < 3.0 mmol/L0
Potassium > 5.5 mmol/L2
Sodium < 130 mmol/L0
Sodium > 150 mmol/L0
Triglycerides > 3.4 mmol/L22
Hemoglobin: Female < 85 g/L, Male < 105 g/L1
Hemoglobin: Female > 170 g/L, Male > 185 g/L0
Leukocytes < 1.5 × 10^9/L0
Lymphocytes < 0.8 × 10^9/L3
Neutrophils, Segmented < 1.0 × 10^9/L0
Platelets < 75 × 10^9/L2
Platelets > 600 × 10^9/L0
SecondaryChange From Baseline in Blood Pressure at End of Apremilast Extension Period
Time frame:
Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Reported as:
Mean · mmHg
Change From Baseline in Blood Pressure at End of Apremilast Extension Period
mmHgApremilast 30 mg
Systolic0.1 ± 13.68
Diastolic0.1 ± 8.98
SecondaryChange From Baseline in Pulse Rate at End of Apremilast Extension Period
Time frame:
Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Reported as:
Mean · beats/minute
Change From Baseline in Pulse Rate at End of Apremilast Extension Period
beats/minuteApremilast 30 mg
Change From Baseline in Pulse Rate at End of Apremilast Extension Period1.0 ± 10.29
SecondaryChange From Baseline in Body Weight at End of Apremilast Extension Period
Time frame:
Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Reported as:
Mean · kg
Change From Baseline in Body Weight at End of Apremilast Extension Period
kgApremilast 30 mg
Change From Baseline in Body Weight at End of Apremilast Extension Period-1.20 ± 3.802
SecondaryChange From Baseline in Waist Circumference at End of Apremilast Extension Period
Time frame:
Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Reported as:
Mean · cm
Change From Baseline in Waist Circumference at End of Apremilast Extension Period
cmApremilast 30 mg
Change From Baseline in Waist Circumference at End of Apremilast Extension Period-0.8 ± 4.97

Adverse events

Collected over Placebo-controlled period: From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period. Apremilast extension period: From first dose of apremilast in the extension period to 28 days after last dose, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Period: Placebo0/92 (0%)0/92 (0%)38/92 (41.3%)
Placebo-controlled Period: Apremilast 30 mg0/185 (0%)8/185 (4.3%)113/185 (61.1%)
Apremilast Extension Period: Apremilast 30 mg0/221 (0%)12/221 (5.4%)93/221 (42.1%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast 30 mgApremilast Extension Period: Apremilast 30 mg
COVID-19 pneumoniaInfections and infestations0/922/1850/221
Atrial fibrillationCardiac disorders0/921/1850/221
IridocyclitisEye disorders0/921/1850/221
Pancreatitis acuteGastrointestinal disorders0/921/1850/221
Cerebral infarctionNervous system disorders0/921/1850/221
SyncopeNervous system disorders0/921/1850/221
Renal colicRenal and urinary disorders0/921/1850/221
Peripheral ischaemiaVascular disorders0/921/1850/221
Abdominal painGastrointestinal disorders0/920/1851/221
FaecalomaGastrointestinal disorders0/920/1851/221
Most frequent other events
Most frequent other events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: Apremilast 30 mgApremilast Extension Period: Apremilast 30 mg
DiarrhoeaGastrointestinal disorders6/9261/18522/221
NauseaGastrointestinal disorders5/9237/18510/221
HeadacheNervous system disorders5/9237/18519/221
NasopharyngitisInfections and infestations11/9218/18525/221
PsoriasisSkin and subcutaneous tissue disorders10/925/18520/221
Abdominal pain upperGastrointestinal disorders4/9212/1853/221
Back painMusculoskeletal and connective tissue disorders4/926/18512/221
Abdominal painGastrointestinal disorders1/9210/1854/221

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Placebo / Apremilast 30 mgApremilast 30 mgTotal
Mean50.9 ± 13.6847.4 ± 14.2848.6 ± 14.16
Age, Customized
Age, Customized(Participants)Placebo / Apremilast 30 mgApremilast 30 mgTotal
< 65 years73158231
≥ 65 years192746
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / Apremilast 30 mgApremilast 30 mgTotal
Female3579114
Male57106163
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo / Apremilast 30 mgApremilast 30 mgTotal
White89179268
Black or African American022
Asian112
Not Collected or Unknown235
Region of Enrollment
Region of Enrollment(Participants)Placebo / Apremilast 30 mgApremilast 30 mgTotal
France61319
Germany45102147
Italy81119
Spain232447
Switzerland178
United Kingdom92837
Duration of Plaque Psoriasis
Duration of Plaque Psoriasis(years)Placebo / Apremilast 30 mgApremilast 30 mgTotal
Mean18.41 ± 13.35016.31 ± 13.11617.01 ± 13.207
Primary Manifestations for Stratifications
Primary Manifestations for Stratifications(Participants)Placebo / Apremilast 30 mgApremilast 30 mgTotal
Scalp Psoriasis234568
Nail Psoriasis204060
Palmoplantar Psoriasis102232
Genital Psoriasis152843
Psoriasis in Visible Locations245074
Dermatology Life Quality Index (DLQI) Score
Dermatology Life Quality Index (DLQI) Score(score on a scale)Placebo / Apremilast 30 mgApremilast 30 mgTotal
Mean18.5 ± 4.9418.1 ± 4.8618.2 ± 4.88
08

Study locations

72 sites
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Grenoble, 38043, France
  • Research Site
    Lyon, 69437, France
  • Research Site
    Paris, 75475, France
  • Research Site
    Pringy, 74374, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Saint-Priest-en-Jarez, 42270, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Valence, 26953, France
  • Research Site
    Valenciennes, 72037, France
  • Research Site
    Aachen, 52074, Germany
  • Research Site
    Augsburg, 86179, Germany
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Berlin, 10247, Germany
  • Research Site
    Berlin, 13086, Germany
  • Research Site
    Berlin, 13507, Germany
  • Research Site
    Bochum, 44803, Germany
  • Research Site
    Bonn, 53111, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Frankfurt am Main, 60590, Germany
  • Research Site
    Gera, 07548, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Heidelberg, 69115, Germany
  • Research Site
    Jena, 07743, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Langenau, 89129, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    München, 80802, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Naples, 80138, Italy
  • Research Site
    Napoli, Campania, 80131, Italy
  • Research Site
    Perugia, 06129, Italy
  • Research Site
    Roma, 00133, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Badalona, Catalonia 08916, Spain
  • Research Site
    Alcorcón, Madrid 28922, Spain
  • Research Site
    Fuenlabrada, Madrid 28942, Spain
  • Research Site
    Alicante, Valencia 03010, Spain
  • Research Site
    Manises, Valencia 46940, Spain
  • Research Site
    Castellon, 12004, Spain
  • Research Site
    Lugo, 27003, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Murcia, 30008, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Seville, 41014, Spain
  • Research Site
    Lausanne, 1011, Switzerland
  • Research Site
    Zurich, 8091, Switzerland
  • Research Site
    Barnet, EN5 3DJ, United Kingdom
  • Research Site
    Birmingham, B15 2WB, United Kingdom
  • Research Site
    Brighton, BN2 3EW, United Kingdom
  • Research Site
    Bury St Edmunds, IP33 2QZ, United Kingdom
  • Research Site
    Dumfries, DG1 4AP, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Gloucester, GL1 3NN, United Kingdom
  • Research Site
    Isleworth, TW7 6AF, United Kingdom
  • Research Site
    Leeds, LS7 4SA, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Newport, NP18 3XQ, United Kingdom
  • Research Site
    Nottingham, NG7 2UH, United Kingdom
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
  • Research Site
    Redhill, RH1 5RH, United Kingdom
  • Research Site
    Southampton, SO16 6YD, United Kingdom
  • Research Site
    Stourbridge, DY8 4JB, United Kingdom
09

References and documents

Publications

  • Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, Reddy J, Paris M, Picard H, Jardon S, Augustin M. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):348-355. doi: 10.1111/jdv.18689. Epub 2022 Nov 14. PubMed 36300769 ↗
  • Augustin M, Barker J, Conrad C, Jullien D, Carrascosa JM, Reddy J, Amouzadeh H, Colgan S, Zou H, Mrowietz U. Efficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life. Dermatol Ther (Heidelb). 2025 Jul;15(7):1915-1929. doi: 10.1007/s13555-025-01389-z. Epub 2025 May 3. PubMed 40317400 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Feb 2021, 22 months.

Results were first posted in Jan 2022, 11 months after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 13, 2018
StartActual
Mar 28, 2019
Primary completionActual
Feb 1, 2021
CompletionActual
Nov 3, 2021
Results first posted
Jan 13, 2022
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03774875
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 13, 2018
Start date
Mar 28, 2019
Primary completion
Feb 1, 2021
Completion
Nov 3, 2021
Results posted
Jan 13, 2022
Last update
Jul 10, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion